Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival

NCT07731425 | Not Yet Recruiting

• 1 other identifier: 714377A
• Study Type: interventional
• Target: 3,000
• Locations: 1 country
• Sites: 1

Brief Summary

This study of current or former cancer patients will evaluate whether communicating data on overall survival data in addition to information on progression-free improves the accuracy of cancer patients' expectations about the survival benefits of new cancer drugs

Conditions

Cancer

Keywords

cancer; prescription drugs; progression-free survival

Outcome Measures

Primary Outcomes (1)

• Accuracy of expectations about the survival benefits of a new cancer drug approved based on progression-free survival

  Compared to standard treatment, do patients with advanced kidney cancer live longer when treated with Velotrex? \- Response options: definitely yes, probably yes, probably no, definitely no

  Assessed immediately after the intervention

Secondary Outcomes (1)

• Perceptions of drug benefits and risks

  Assessed immediately after the intervention

Study Arms (6)

FDA explanation for progression-free survival (control)

PLACEBO COMPARATOR

Other: FDA explanation for progression-free survival (control)

FDA explanation for progression-free survival with overall survival data

EXPERIMENTAL

Other: FDA explanation for progression-free survival with overall survival data

NCI explanation for progression-free survival

EXPERIMENTAL

Other: NCI explanation for progression-free survival

NCI explanation for progression-free survival with overall survival data

EXPERIMENTAL

Other: NCI explanation for progression-free survival with overall survival data

Plain-language explanation of progression-free survival

EXPERIMENTAL

Other: Plain-language explanation of progression-free survival

Plain-language explanation of progression-free survival with overall survival data

EXPERIMENTAL

Other: Plain-language explanation of progression-free survival with overall survival data

Interventions

FDA explanation for progression-free survival (control) OTHER

Progression-free survival

FDA explanation for progression-free survival (control)

FDA explanation for progression-free survival with overall survival data OTHER

The description, 'progression-free survival', along with data on overall survival.

FDA explanation for progression-free survival with overall survival data

NCI explanation for progression-free survival OTHER

The description, 'the length of time during and after treatment that a patient lived with the cancer but it did not get worse'.

NCI explanation for progression-free survival

NCI explanation for progression-free survival with overall survival data OTHER

The description, 'the length of time during and after treatment that a patient lived with the cancer but it did not get worse', along with data on overall survival.

NCI explanation for progression-free survival with overall survival data

Plain-language explanation of progression-free survival OTHER

The description, 'the length of time until a test showed the cancer grew, spread, or worsened'.

Plain-language explanation of progression-free survival

Plain-language explanation of progression-free survival with overall survival data OTHER

The description, 'the length of time until a test showed the cancer grew, spread, or worsened', along with data on overall survival.

Plain-language explanation of progression-free survival with overall survival data

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• US adults with a current or former cancer diagnosis (excluding nonmelanoma skin cancer)
• US adults 18 years of age and older, fluent in English, and residing in the United States.

Sponsors & Collaborators

• London School of Economics and Political Science: lead
• Harvard Medical School and Harvard Pilgrim Health Care Institute: collaborator

Study Sites (1)

Harvard Medical School and Harvard Pilgrim Health Care Institute

Boston, Massachusetts, 02215, United States

Location

MeSH Terms

Conditions

Neoplasms

Interventions

Progression-Free Survival

Intervention Hierarchy (Ancestors)

Treatment Outcome; Prognosis; Diagnosis; Survival Analysis; Statistics as Topic; Epidemiologic Methods; Investigative Techniques; Outcome Assessment, Health Care; Outcome and Process Assessment, Health Care; Quality of Health Care; Health Services Administration; Health Care Evaluation Mechanisms; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Central Study Contacts

Avi Cherla

CONTACT

020 7955 7975; avi_cherla@hphci.harvard.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Research Fellow

Study Record Dates

• First Submitted: July 23, 2026
• First Posted: July 28, 2026
• Study Start: August 1, 2026
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026
• Last Updated: July 28, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)